Highest-materiality recent filing
Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end
Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).
Q4 revenue $12.5B (+1% YoY); Growth Portfolio rev $7.4B (+16%). Full-year rev $48.2B.
BMY completes early settlement of ~$7.5B tender offers for 15 note series
Amended Pool 1 max purchase price to ~$3.99B; Pool 2 max to ~$3.51B.
Bristol-Myers Squibb launches $7B cash tender offer for 15 series of outstanding notes
Offers up to $4B for Pool 1 notes (2026-2029 maturities) and $3B for Pool 2 notes (2031-2097).
Bristol Myers Q3 revenue $12.2B (+3% YoY), GAAP EPS $1.08, raises FY revenue guidance to ~$47.5-48B
Total revenues $12,222M (+3% YoY; +2% ex-FX); Growth Portfolio $6.9B (+18% ex-FX).
BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance
Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).
Bristol-Myers Squibb Q1 revenue $11.2B (-6% YoY), GAAP EPS $1.20, raises FY guidance
Total revenues $11.2B, down 6% (4% ex-FX) from $11.865B in Q1 2024.
BMY Q4 rev +8% to $12.3B, GAAP EPS $0.04; expands cost-savings by $2B
Q4 2024 revenues $12.3B (+8% YoY, +9% ex-FX); GAAP EPS $0.04, Non-GAAP EPS $1.67.
Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved
Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.
Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance
Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).
Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges
Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).
On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.
On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.
Max materiality 0.85 · Median 0.65 · Most common event earnings